title: Pneumococcal conjugate vaccine in adults: Let's see what happens.
abstract: The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for preventing disease in this at-risk population. The conjugate vaccine induces a T-cell dependent response, which distinguishes it from the polysaccharide vaccine and could provide the longer-term protection necessary to have a significant impact in this population.
authors.affiliation: a Paradiso Biologics Consulting, LLC , Radnor , PA , USA.
authors.forename: Peter R
authors.initials: PR
authors.lastname: Paradiso
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines